Open AccessElevation of Serum MAGE‐4 Protein Levels and Prediction of Hepatocellular Carcinogenesis in Patients with Liver Cirrhosis
Author(s) -
Yutani Shigeru,
Tanaka Masatoshi,
Mutsumoto Hajime,
Imai Nobue,
Sata Michio,
Shichijo Shigeki,
Harada Mamoru,
Itoh Kyogo
Publication year - 2002
Publication title -
japanese journal of cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 0910-5050
DOI - 10.1111/j.1349-7006.2002.tb01277.x
Subject(s) - hepatocellular carcinoma , cirrhosis , medicine , gastroenterology , univariate analysis , carcinogenesis , stage (stratigraphy) , liver cancer , cancer , pathology , multivariate analysis , biology , paleontology
Early detection of hepatocellular carcinoma (HCC) is clinically important because advanced HCC limits treatment modalities for the cancer. We have previously reported that serum levels of MAGE‐4 protein are strongly associated with the development of HCC. The present study was designed to determine whether elevated serum MAGE‐4 protein levels can predict hepatocellular carcinogenesis in patients with liver cirrhosis before clinical diagnosis. Among 62 cirrhotic patients, 28 patients were diagnosed with HCC during the follow‐up period. The levels of MAGE‐4 protein and a‐fetoprotein (AFP) were significantly elevated in cirrhotic patients with HCC. Univariate and multivariate analyses suggest that elevated serum MAGE‐4 protein is more significant than AFP. Importantly, retrospective analysis of prefrozen sera of cirrhotic patients revealed a transient or continuous elevation of serum MAGE‐4 protein levels in 14 of 28 cirrhotic patients with HCC (50%) before clinical diagnosis. In contrast, elevated serum MAGE‐4 protein levels were observed in 3 of 33 cirrhotic patients without HCC (9%), and in 2 of 34 hepatitic patients (6%). These results indicate that elevated serum MAGE‐4 protein levels can be a predictive marker of hepatocellular carcinogenesis in cirrhotic patients, thereby enabling us to treat patients at an earlier stage.